Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 3/2018

16.11.2017 | Review

Considerations and guidelines for mouse metabolic phenotyping in diabetes research

verfasst von: Thierry Alquier, Vincent Poitout

Erschienen in: Diabetologia | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Mice are the most commonly used species in preclinical research on the pathophysiology of metabolic diseases. Although they are extremely useful for identifying pathways, mechanisms and genes regulating glucose and energy homeostasis, the specificities of the various mouse models and methodologies used to investigate a metabolic phenotype can have a profound impact on experimental results and their interpretation. This review aims to: (1) describe the most commonly used experimental tests to assess glucose and energy homeostasis in mice; (2) provide some guidelines regarding the design, analysis and interpretation of these tests, as well as for studies using genetic models; and (3) identify important caveats and confounding factors that must be taken into account in the interpretation of findings.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Lee AW, Cox RD (2011) Use of mouse models in studying type 2 diabetes mellitus. Expert Rev Mol Med 13:e1CrossRefPubMed
2.
King A, Bowe J (2016) Animal models for diabetes: understanding the pathogenesis and finding new treatments. Biochem Pharmacol 99:1–10CrossRefPubMed
3.
Leulier F, MacNeil LT, Lee WJ et al (2017) Integrative physiology: at the crossroads of nutrition, microbiota, animal physiology, and human health. Cell Metab 25:522–534CrossRefPubMed
4.
Drucker DJ (2016) Never waste a good crisis: confronting reproducibility in translational research. Cell Metab 24:348–360CrossRefPubMed
5.
Flier JS (2017) Irreproducibility of published bioscience research: diagnosis, pathogenesis and therapy. Mol Metab 6:2–9CrossRefPubMed
6.
Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J (2008) Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab 295:E1323–E1332CrossRefPubMed
7.
McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH (2009) NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. Am J Physiol Endocrinol Metab 297:E849–E855CrossRefPubMedPubMedCentral
8.
Ayala JE, Samuel VT, Morton GJ et al (2010) Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech 3:525–534CrossRefPubMedPubMedCentral
9.
10.
Bowe JE, Franklin ZJ, Hauge-Evans AC, King AJ, Persaud SJ, Jones PM (2014) Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models. J Endocrinol 222:G13–G25CrossRefPubMed
11.
Lee HY, Jeong KH, Choi CS, International Mouse Phenotyping Consortium (2014) In-depth metabolic phenotyping of genetically engineered mouse models in obesity and diabetes. Mamm Genome 25:508–521CrossRefPubMed
12.
Ayala JE, Bracy DP, McGuinness OP, Wasserman DH (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390–397CrossRefPubMed
13.
Omar BA, Pacini G, Ahren B (2014) Impact of glucose dosing regimens on modeling of glucose tolerance and β-cell function by intravenous glucose tolerance test in diet-induced obese mice. Phys Rep 2:e12011CrossRef
14.
15.
Lee S, Muniyappa R, Yan X et al (2008) Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab 294:E261–E270CrossRefPubMed
16.
Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN (1996) Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19:1018–1030CrossRefPubMed
17.
Andrikopoulos S, Massa CM, Aston-Mourney K et al (2005) Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. J Endocrinol 187:45–53CrossRefPubMed
18.
Aston-Mourney K, Wong N, Kebede M et al (2007) Increased nicotinamide nucleotide transhydrogenase levels predispose to insulin hypersecretion in a mouse strain susceptible to diabetes. Diabetologia 50:2476–2485CrossRefPubMed
19.
Latour MG, Alquier T, Oseid E et al (2007) GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56:1087–1094CrossRefPubMedPubMedCentral
20.
Morton GJ, Matsen ME, Bracy DP et al (2013) FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 123:4799–4808CrossRefPubMedPubMedCentral
21.
Fergusson G, Ethier M, Guevremont M et al (2014) Defective insulin secretory response to intravenous glucose in C57Bl/6J compared to C57Bl/6N mice. Mol Metab 3:848–854CrossRefPubMedPubMedCentral
22.
Attane C, Peyot ML, Lussier R et al (2016) Differential insulin secretion of high-fat diet-fed C57BL/6NN and C57BL/6NJ mice: implications of mixed genetic background in metabolic studies. PLoS One 11:e0159165CrossRefPubMedPubMedCentral
23.
Korsgren E, Korsgren O (2016) Glucose effectiveness: the mouse trap in the development of novel ss-cell replacement therapies. Transplantation 100:111–115CrossRefPubMed
24.
Wong N, Blair AR, Morahan G, Andrikopoulos S (2010) The deletion variant of nicotinamide nucleotide transhydrogenase (Nnt) does not affect insulin secretion or glucose tolerance. Endocrinology 151:96–102CrossRefPubMed
25.
Kahn SE, Prigeon RL, McCulloch DK et al (1994) The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43:587–592CrossRefPubMed
26.
27.
Alonso LC, Watanabe Y, Stefanovski D et al (2012) Simultaneous measurement of insulin sensitivity, insulin secretion, and the disposition index in conscious unhandled mice. Obesity 20:1403–1412CrossRefPubMedPubMedCentral
28.
Hughey CC, Wasserman DH, Lee-Young RS, Lantier L (2014) Approach to assessing determinants of glucose homeostasis in the conscious mouse. Mamm Genome 25:522–538CrossRefPubMedPubMedCentral
29.
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Phys 237:E214–E223
30.
Pepin E, Higa A, Schuster-Klein C et al (2014) Deletion of apoptosis signal-regulating kinase 1 (ASK1) protects pancreatic beta-cells from stress-induced death but not from glucose homeostasis alterations under pro-inflammatory conditions. PLoS One 9:e112714CrossRefPubMedPubMedCentral
31.
Mulligan KX, Morris RT, Otero YF, Wasserman DH, McGuinness OP (2012) Disassociation of muscle insulin signaling and insulin-stimulated glucose uptake during endotoxemia. PLoS One 7:e30160CrossRefPubMedPubMedCentral
32.
Moulle VS, Vivot K, Tremblay C, Zarrouki B, Ghislain J, Poitout V (2017) Glucose and fatty acids synergistically and reversibly promote beta cell proliferation in rats. Diabetologia 60:879–888CrossRefPubMed
33.
Steil GM, Volund A, Kahn SE, Bergman RN (1993) Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 42:250–256CrossRefPubMed
34.
35.
Lamontagne J, Jalbert-Arsenault E, Pepin E et al (2013) Pioglitazone acutely reduces energy metabolism and insulin secretion in rats. Diabetes 62:2122–2129CrossRefPubMedPubMedCentral
36.
Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19CrossRefPubMed
37.
Fontes G, Ghislain J, Benterki I et al (2015) The ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator is associated with progressive insulin resistance and decreased functional β-cell mass in mice. Diabetes 64:4112–4122CrossRefPubMedPubMedCentral
38.
Alquier T, Peyot ML, Latour MG et al (2009) Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58:2607–2615CrossRefPubMedPubMedCentral
39.
Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V (2008) The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57:2432–2437CrossRefPubMedPubMedCentral
40.
Lan H, Hoos LM, Liu L et al (2008) Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57:2999–3006CrossRefPubMedPubMedCentral
41.
Matsuda-Nagasumi K, Takami-Esaki R, Iwachidow K et al (2013) Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition. Diabetes Obes Metab 15:538–545CrossRefPubMed
42.
Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467CrossRefPubMedPubMedCentral
43.
44.
45.
Moir L, Bentley L, Cox RD (2016) Comprehensive energy balance measurements in mice. Curr Protoc Mouse Biol 6:211–222CrossRefPubMed
46.
Ganeshan K, Chawla A (2017) Warming the mouse to model human diseases. Nat Rev Endocrinol 13:458–465CrossRefPubMed
47.
Toth LA (2015) The influence of the cage environment on rodent physiology and behavior: implications for reproducibility of pre-clinical rodent research. Exp Neurol 270:72–77CrossRefPubMed
48.
Dudele A, Rasmussen GM, Mayntz D, Malte H, Lund S, Wang T (2015) Effects of ambient temperature on glucose tolerance and insulin sensitivity test outcomes in normal and obese C57 male mice. Phys Rep 3:e12396CrossRef
49.
Cui X, Nguyen NL, Zarebidaki E et al (2016) Thermoneutrality decreases thermogenic program and promotes adiposity in high-fat diet-fed mice. Phys Rep 4:e12799CrossRef
50.
Butler AA, Kozak LP (2010) A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes 59:323–329CrossRefPubMedPubMedCentral
51.
Kaiyala KJ, Morton GJ, Leroux BG, Ogimoto K, Wisse B, Schwartz MW (2010) Identification of body fat mass as a major determinant of metabolic rate in mice. Diabetes 59:1657–1666CrossRefPubMedPubMedCentral
52.
Ambery AG, Tackett L, Penque BA, Hickman DL, Elmendorf JS (2014) Effect of corncob bedding on feed conversion efficiency in a high-fat diet-induced prediabetic model in C57Bl/6J mice. J Am Assoc Lab Anim Sci 53:449–451PubMedPubMedCentral
53.
Davies J (2009) Regulation, necessity, and the misinterpretation of knockouts. BioEssays 31:826–830CrossRefPubMed
54.
55.
Tschen SI, Dhawan S, Gurlo T, Bhushan A (2009) Age-dependent decline in β-cell proliferation restricts the capacity of β-cell regeneration in mice. Diabetes 58:1312–1320CrossRefPubMedPubMedCentral
56.
Fontes G, Zarrouki B, Hagman DK et al (2010) Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass. Diabetologia 53:2369–2379CrossRefPubMedPubMedCentral
57.
Zarrouki B, Benterki I, Fontes G et al (2014) Epidermal growth factor receptor signaling promotes pancreatic β-cell proliferation in response to nutrient excess in rats through mTOR and FOXM1. Diabetes 63:982–993CrossRefPubMedPubMedCentral
58.
Mauvais-Jarvis F, Clegg DJ, Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34:309–338CrossRefPubMedPubMedCentral
59.
Palmer BF, Clegg DJ (2015) The sexual dimorphism of obesity. Mol Cell Endocrinol 402:113–119CrossRefPubMed
60.
Della Torre S, Maggi A (2017) Sex differences: a resultant of an evolutionary pressure? Cell Metab 25:499–505CrossRefPubMed
61.
McCullough LD, de Vries GJ, Miller VM, Becker JB, Sandberg K, McCarthy MM (2014) NIH initiative to balance sex of animals in preclinical studies: generative questions to guide policy, implementation, and metrics. Biol Sex Differ 5:15CrossRefPubMedPubMedCentral
62.
Mauvais-Jarvis F, Arnold AP, Reue K (2017) A guide for the design of pre-clinical studies on sex differences in metabolism. Cell Metab 25:1216–1230CrossRefPubMed
63.
Ader DN, Johnson SB, Huang SW, Riley WJ (1991) Group size, cage shelf level, and emotionality in non-obese diabetic mice: impact on onset and incidence of IDDM. Psychosom Med 53:313–321CrossRefPubMed
64.
Ussar S, Fujisaka S, Kahn CR (2016) Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. Mol Metab 5:795–803CrossRefPubMedPubMedCentral
65.
Grarup N, Sandholt CH, Hansen T, Pedersen O (2014) Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond. Diabetologia 57:1528–1541CrossRefPubMed
66.
Alarcon C, Boland BB, Uchizono Y et al (2016) Pancreatic β-cell adaptive plasticity in obesity increases insulin production but adversely affects secretory function. Diabetes 65:438–450CrossRefPubMed
67.
Sittig LJ, Carbonetto P, Engel KA, Krauss KS, Barrios-Camacho CM, Palmer AA (2016) Genetic background limits generalizability of genotype-phenotype relationships. Neuron 91:1253–1259CrossRefPubMedPubMedCentral
68.
Cruciani-Guglielmacci C, Bellini L, Denom J et al (2017) Molecular phenotyping of multiple mouse strains under metabolic challenge uncovers a role for Elovl2 in glucose-induced insulin secretion. Mol Metab 6:340–351CrossRefPubMedPubMedCentral
69.
Kebede MA, Attie AD (2014) Insights into obesity and diabetes at the intersection of mouse and human genetics. Trends Endocrinol Metab 25:493–501CrossRefPubMedPubMedCentral
70.
71.
Freeman H, Shimomura K, Horner E, Cox RD, Ashcroft FM (2006) Nicotinamide nucleotide transhydrogenase: a key role in insulin secretion. Cell Metab 3:35–45CrossRefPubMed
72.
Nicholson A, Reifsnyder PC, Malcolm RD et al (2010) Diet-induced obesity in two C57BL/6 substrains with intact or mutant nicotinamide nucleotide transhydrogenase (Nnt) gene. Obesity 18:1902–1905CrossRefPubMedPubMedCentral
73.
Fontaine DA, Davis DB (2016) Attention to background strain is essential for metabolic research: C57BL/6 and the international knockout mouse consortium. Diabetes 65:25–33CrossRefPubMed
74.
Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H (2005) The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 1:245–258CrossRefPubMed
75.
Nagasumi K, Esaki R, Iwachidow K et al (2009) Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58:1067–1076CrossRefPubMedPubMedCentral
76.
Oh DY, Talukdar S, Bae EJ et al (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:687–698CrossRefPubMedPubMedCentral
77.
Bjursell M, Xu X, Admyre T et al (2014) The beneficial effects of n-3 polyunsaturated fatty acids on diet induced obesity and impaired glucose control do not require Gpr120. PLoS One 9:e114942CrossRefPubMedPubMedCentral
78.
Paerregaard SI, Agerholm M, Serup AK et al (2016) FFAR4 (GPR120) signaling is not required for anti-inflammatory and insulin-sensitizing effects of omega-3 fatty acids. Mediat Inflamm 2016:1536047CrossRef
79.
Pi J, Collins S (2010) Reactive oxygen species and uncoupling protein 2 in pancreatic β-cell function. Diabetes Obes Metab 12(Suppl 2):141–148CrossRefPubMed
80.
Seshadri N, Jonasson ME, Hunt KL et al (2017) Uncoupling protein 2 regulates daily rhythms of insulin secretion capacity in MIN6 cells and isolated islets from male mice. Mol Metab 6:760–769CrossRefPubMedPubMedCentral
81.
Pugach EK, Richmond PA, Azofeifa JG, Dowell RD, Leinwand LA (2015) Prolonged cre expression driven by the alpha-myosin heavy chain promoter can be cardiotoxic. J Mol Cell Cardiol 86:54–61CrossRefPubMedPubMedCentral
82.
83.
Rebholz SL, Jones T, Burke KT et al (2012) Multiparity leads to obesity and inflammation in mothers and obesity in male offspring. Am J Physiol Endocrinol Metab 302:E449–E457CrossRefPubMed
84.
Abel ED, Peroni O, Kim JK et al (2001) Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409:729–733CrossRefPubMed
85.
Harno E, Cottrell EC, White A (2013) Metabolic pitfalls of CNS cre-based technology. Cell Metab 18:21–28CrossRefPubMed
86.
87.
Lee JY, Ristow M, Lin X, White MF, Magnuson MA, Hennighausen L (2006) RIP-cre revisited, evidence for impairments of pancreatic β-cell function. J Biol Chem 281:2649–2653CrossRefPubMed
88.
Wicksteed B, Brissova M, Yan W et al (2010) Conditional gene targeting in mouse pancreatic β-cells: analysis of ectopic cre transgene expression in the brain. Diabetes 59:3090–3098CrossRefPubMedPubMedCentral
89.
Oropeza D, Jouvet N, Budry L et al (2015) Phenotypic characterization of MIP-creERT1Lphi mice with transgene-driven islet expression of human growth hormone. Diabetes 64:3798–3807CrossRefPubMedPubMedCentral
90.
Thorens B, Tarussio D, Maestro MA, Rovira M, Heikkila E, Ferrer J (2015) Ins1(cre) knock-in mice for beta cell-specific gene recombination. Diabetologia 58:558–565CrossRefPubMed
91.
Shiota C, Prasadan K, Guo P, Fusco J, Xiao X, Gittes GK (2017) Gcg creERT2 knockin mice as a tool for genetic manipulation in pancreatic alpha cells. Diabetologia 60:2399–2408
92.
Schulz TJ, Glaubitz M, Kuhlow D et al (2007) Variable expression of cre recombinase transgenes precludes reliable prediction of tissue-specific gene disruption by tail-biopsy genotyping. PLoS One 2:e1013CrossRefPubMedPubMedCentral
93.
Douglass JD, Dorfman MD, Fasnacht R, Shaffer LD, Thaler JP (2017) Astrocyte IKKbeta/NF-kappaB signaling is required for diet-induced obesity and hypothalamic inflammation. Mol Metab 6:366–373CrossRefPubMedPubMedCentral
94.
Brouwers B, de Faudeur G, Osipovich AB et al (2014) Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. Cell Metab 20:979–990CrossRefPubMedPubMedCentral
95.
Declercq J, Brouwers B, Pruniau VP et al (2015) Metabolic and behavioural phenotypes in nestin-cre mice are caused by hypothalamic expression of human growth hormone. PLoS One 10:e0135502CrossRefPubMedPubMedCentral
96.
Koitabashi N, Bedja D, Zaiman AL et al (2009) Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res 105:12–15CrossRefPubMedPubMedCentral
97.
Morimoto M, Kopan R (2009) rtTA toxicity limits the usefulness of the SP-C-rtTA transgenic mouse. Dev Biol 325:171–178CrossRefPubMed
98.
Bersell K, Choudhury S, Mollova M et al (2013) Moderate and high amounts of tamoxifen in αMHC-MerCreMer mice induce a DNA damage response, leading to heart failure and death. Dis Model Mech 6:1459–1469CrossRefPubMedPubMedCentral
99.
Metadaten
Titel
Considerations and guidelines for mouse metabolic phenotyping in diabetes research
verfasst von
Thierry Alquier
Vincent Poitout
Publikationsdatum
16.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 3/2018
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4495-9

Weitere Artikel der Ausgabe 3/2018

Diabetologia 3/2018 Zur Ausgabe

Article

Associations between birthweight, gestational age at birth and subsequent type 1 diabetes in children under 12: a retrospective cohort study in England, 1998–2012

Article

Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort

Article

Development and characterisation of a novel glucagon like peptide-1 receptor antibody

Short Communication

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

Review

Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach

Article

Adapting to insulin resistance in obesity: role of insulin secretion and clearance

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise